Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T13:35:46.991Z.
Calculation as of: 2026-10-06T13:35:46.991Z.
Quote observation: 2026-10-06T13:34:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$11.21M
EV/Sales Ratio
N/A
TTM Avg
2.30x
3Y Avg
2.30x
5Y Avg
5910.26x
Market Cap
$10.86M
EV/Sales Ratio
N/A
TTM Avg
30.14x
3Y Avg
54.00x
5Y Avg
56.96x
Market Cap
$11.39M
EV/Sales Ratio
9.45x
TTM Avg
63.85x
3Y Avg
37.14x
5Y Avg
37.14x
Market Cap
$10.68M
EV/Sales Ratio
12.90x
TTM Avg
73.67x
3Y Avg
220.77x
5Y Avg
480.05x
Market Cap
$11.65M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.07M
EV/Sales Ratio
0.91x
TTM Avg
1.49x
3Y Avg
1.84x
5Y Avg
2.28x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $11.09M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | N/A | 2.30x | 2.30x | 5910.26x |
| Biofrontera Inc. (BFRI)vs › | $11.27M | 0.31x | 0.30x | 0.19x | 0.34x |
| Cerenome, Inc. (CNSY)vs › | $11.29M | 2.13x | 3.91x | 3.91x | 3.91x |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.86M | N/A | 30.14x | 54.00x | 56.96x |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.39M | 9.45x | 63.85x | 37.14x | 37.14x |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $10.68M | 12.90x | 73.67x | 220.77x | 480.05x |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.65M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.07M | 0.91x | 1.49x | 1.84x | 2.28x |
| Caring Brands, Inc. (CABR)vs › | $10.09M | 7130.35x | 8299.41x | 8299.41x | 8299.41x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
